Cargando…

Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes

To describe the development and implementation of a new digital health clinical tool (Gynecologic Survivorship Tool [GST]) for symptom management of women surgically treated for gynecologic cancer; to assess its feasibility; and to conduct a retrospective review of the data. MATERIALS AND METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Jeanne, Abu-Rustum, Nadeem R., Saban, Sally, Chen, Ling Y., Vickers, Andrew J., Tin, Amy L., Billanti, Gabriela, Connors, Nicole A., Broach, Vance, Brown, Carol L., Chi, Dennis S., Gardner, Ginger J., Goldfrank, Deborah J., Jewell, Elizabeth L., Leitao, Mario M., Long Roche, Kara C., Mueller, Jennifer J., Sonoda, Yukio, Zivanovic, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920469/
https://www.ncbi.nlm.nih.gov/pubmed/35239413
http://dx.doi.org/10.1200/CCI.21.00154
_version_ 1784669134260273152
author Carter, Jeanne
Abu-Rustum, Nadeem R.
Saban, Sally
Chen, Ling Y.
Vickers, Andrew J.
Tin, Amy L.
Billanti, Gabriela
Connors, Nicole A.
Broach, Vance
Brown, Carol L.
Chi, Dennis S.
Gardner, Ginger J.
Goldfrank, Deborah J.
Jewell, Elizabeth L.
Leitao, Mario M.
Long Roche, Kara C.
Mueller, Jennifer J.
Sonoda, Yukio
Zivanovic, Oliver
author_facet Carter, Jeanne
Abu-Rustum, Nadeem R.
Saban, Sally
Chen, Ling Y.
Vickers, Andrew J.
Tin, Amy L.
Billanti, Gabriela
Connors, Nicole A.
Broach, Vance
Brown, Carol L.
Chi, Dennis S.
Gardner, Ginger J.
Goldfrank, Deborah J.
Jewell, Elizabeth L.
Leitao, Mario M.
Long Roche, Kara C.
Mueller, Jennifer J.
Sonoda, Yukio
Zivanovic, Oliver
author_sort Carter, Jeanne
collection PubMed
description To describe the development and implementation of a new digital health clinical tool (Gynecologic Survivorship Tool [GST]) for symptom management of women surgically treated for gynecologic cancer; to assess its feasibility; and to conduct a retrospective review of the data. MATERIALS AND METHODS: The GST was developed on the basis of a comprehensive review of the literature, multidisciplinary expert opinion, and feedback from women with a history of gynecologic cancer. It is composed of 17 questions addressing six main categories—gynecologic health (abnormal bleeding/pain), lymphedema, vaginal/vulvar dryness, sexual health, menopause (hot flushes/sleep difficulties), and bowel/urinary issues. An electronic version using the Memorial Sloan Kettering Cancer Center Engage platform was piloted in two clinics for patients with endometrial or cervical cancer. Health information was generated into clinical summaries and identified concerns for actionable response. Associations of symptom and survey time point were assessed by longitudinal models using generalized estimating equations. RESULTS: From January 1, 2019, to February 29, 2020, 3,357 GST assessments were assigned to 1,405 patients, with a 71% completion rate (90% within 5 minutes). Sixty-eight percent were performed at home via a patient portal, 32% at follow-ups using a clinic iPad. The most common symptoms were bowel problems, swelling/fluid, pain during examination, vaginal or vulvar dryness, and vaginal bleeding. Implementation challenges included improving patient compliance and ensuring that reports were reviewed by all clinical teams. We developed screening e-mails detailing patients whose assessments were due, planned training sessions for multidisciplinary teams, and incorporated feedback on methods for reviewing symptoms reports. CONCLUSION: The GST demonstrated feasibility, a high completion rate, and minimal time commitment. It was an effective electronic reporting mechanism for patients, enabling the medical team to develop specific strategies for alleviating bothersome symptoms during follow-up.
format Online
Article
Text
id pubmed-8920469
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-89204692023-03-03 Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes Carter, Jeanne Abu-Rustum, Nadeem R. Saban, Sally Chen, Ling Y. Vickers, Andrew J. Tin, Amy L. Billanti, Gabriela Connors, Nicole A. Broach, Vance Brown, Carol L. Chi, Dennis S. Gardner, Ginger J. Goldfrank, Deborah J. Jewell, Elizabeth L. Leitao, Mario M. Long Roche, Kara C. Mueller, Jennifer J. Sonoda, Yukio Zivanovic, Oliver JCO Clin Cancer Inform Original Reports To describe the development and implementation of a new digital health clinical tool (Gynecologic Survivorship Tool [GST]) for symptom management of women surgically treated for gynecologic cancer; to assess its feasibility; and to conduct a retrospective review of the data. MATERIALS AND METHODS: The GST was developed on the basis of a comprehensive review of the literature, multidisciplinary expert opinion, and feedback from women with a history of gynecologic cancer. It is composed of 17 questions addressing six main categories—gynecologic health (abnormal bleeding/pain), lymphedema, vaginal/vulvar dryness, sexual health, menopause (hot flushes/sleep difficulties), and bowel/urinary issues. An electronic version using the Memorial Sloan Kettering Cancer Center Engage platform was piloted in two clinics for patients with endometrial or cervical cancer. Health information was generated into clinical summaries and identified concerns for actionable response. Associations of symptom and survey time point were assessed by longitudinal models using generalized estimating equations. RESULTS: From January 1, 2019, to February 29, 2020, 3,357 GST assessments were assigned to 1,405 patients, with a 71% completion rate (90% within 5 minutes). Sixty-eight percent were performed at home via a patient portal, 32% at follow-ups using a clinic iPad. The most common symptoms were bowel problems, swelling/fluid, pain during examination, vaginal or vulvar dryness, and vaginal bleeding. Implementation challenges included improving patient compliance and ensuring that reports were reviewed by all clinical teams. We developed screening e-mails detailing patients whose assessments were due, planned training sessions for multidisciplinary teams, and incorporated feedback on methods for reviewing symptoms reports. CONCLUSION: The GST demonstrated feasibility, a high completion rate, and minimal time commitment. It was an effective electronic reporting mechanism for patients, enabling the medical team to develop specific strategies for alleviating bothersome symptoms during follow-up. Wolters Kluwer Health 2022-03-03 /pmc/articles/PMC8920469/ /pubmed/35239413 http://dx.doi.org/10.1200/CCI.21.00154 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Reports
Carter, Jeanne
Abu-Rustum, Nadeem R.
Saban, Sally
Chen, Ling Y.
Vickers, Andrew J.
Tin, Amy L.
Billanti, Gabriela
Connors, Nicole A.
Broach, Vance
Brown, Carol L.
Chi, Dennis S.
Gardner, Ginger J.
Goldfrank, Deborah J.
Jewell, Elizabeth L.
Leitao, Mario M.
Long Roche, Kara C.
Mueller, Jennifer J.
Sonoda, Yukio
Zivanovic, Oliver
Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
title Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
title_full Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
title_fullStr Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
title_full_unstemmed Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
title_short Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes
title_sort gynecologic survivorship tool: development, implementation, and symptom outcomes
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920469/
https://www.ncbi.nlm.nih.gov/pubmed/35239413
http://dx.doi.org/10.1200/CCI.21.00154
work_keys_str_mv AT carterjeanne gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT aburustumnadeemr gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT sabansally gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT chenlingy gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT vickersandrewj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT tinamyl gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT billantigabriela gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT connorsnicolea gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT broachvance gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT browncaroll gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT chidenniss gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT gardnergingerj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT goldfrankdeborahj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT jewellelizabethl gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT leitaomariom gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT longrochekarac gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT muellerjenniferj gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT sonodayukio gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes
AT zivanovicoliver gynecologicsurvivorshiptooldevelopmentimplementationandsymptomoutcomes